Dr. Trinh On Prostate Cancer Treatment During The COVID-19 Crisis

NewsOncClubAll Oncology NewsMediaInsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsConferencesConference CoverageConference ListingEventsGiants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinarsPartnersPublicationsResourcesInteractive ToolsSponsoredBiomarker ConsortiumSubscribeChoose SpecialtyBiosimilarsBrain CancerBreast CancerBreast CancerCAR T-cell TherapyCOVID-19Disparities in Cancer CareGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGenitourinary CancersGenitourinary CancersGenitourinary CancersGlobal OncologyGynecologic OncologyGynecologic OncologyHead & Neck CancersHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyImmuno-OncologyLung CancerMelanoma & Skin CancerOncology Business ManagementPediatric OncologyPrecision Medicine in Oncology®SarcomasSupportive CareSpotlight -

• In-person and virtual events just for HCPs

Choose SpecialtyBiosimilarsBrain CancerBreast CancerBreast CancerCAR T-cell TherapyCOVID-19Disparities in Cancer CareGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGenitourinary CancersGenitourinary CancersGenitourinary CancersGlobal OncologyGynecologic OncologyGynecologic OncologyHead & Neck CancersHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyImmuno-OncologyLung CancerMelanoma & Skin CancerOncology Business ManagementPediatric OncologyPrecision Medicine in Oncology®SarcomasSupportive Care

• • Spotlight
  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe

Advertisement

Video

September 17, 2020Dr. Trinh on Prostate Cancer Treatment During the COVID-19 Crisis

Author(s):

Quoc-Dien Trinh, MD

In Partnership With:

Quoc-Dien Trinh, MD, discusses current strategies on the treatment of patients with high-risk prostate cancer during the COVID-19 crisis.

Quoc-Dien Trinh, MD, an associate professor of surgery at Harvard Medical School; co-director of the Dana-Farber/Brigham and Women's Prostate Cancer Center; and director the of Ambulatory Clinical Operations in the Division of Urological Surgery at Brigham and Women’s Hospital, discusses current strategies on postponing treatment for patients with high-risk prostate cancer during the COVID-19 crisis.

A lot of literature and some internal or external guidance have been published regarding the postponement of surgery in prostate cancer, says Trinh. However, no clear guidelines inform on how to manage 1 patient versus another. The National Comprehensive Cancer Network guidelines said that patients with low- or intermediate-risk prostate cancers can have their surgeries postponed; however, high-risk patients should receive treatment sooner. Regardless, the recommendations should not be considered clear guidance supported by level 1 evidence, Trinh cautions.

Internally, at the Brigham and Women’s Hospital and Dana-Farber, guidance was crafted to help manage patients with prostate cancer while achieving some consistency among providers. Most physicians could agree that the majority of low- and intermediate-risk patients with prostate cancer can be safely postponed by 4 weeks, 8 weeks, or 12 weeks; that is what was done with the majority of cases at these institutions.

The trickier question is determining what to do for high-risk patients. In some instances, treatment can be immediately administrated as it would normally, despite the risk of COVID-19. However, this should only happen after patients are carefully counseled about the benefits and risks of doing so, says Trinh. 

Alternative plans include giving patients neoadjuvant androgen deprivation therapy, either as part of a clinical trial, such as PROTEUS, or off trial. This will minimize the potential for disease spread, while holding off on treatment because of the crisis has been considered, concludes Trinh.

Related VideosRelated Content AdvertisementDecember 18th 2024

Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

December 11th 2024

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

December 11th 2024

Dana-Farber Researchers to Present Findings at 2024 San Antonio Breast Cancer Symposium

December 10th 2024

Evolving Treatment Strategies: Managing Advanced Prostate Cancer

Related Content AdvertisementDecember 18th 2024

Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

December 11th 2024

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

December 11th 2024

Dana-Farber Researchers to Present Findings at 2024 San Antonio Breast Cancer Symposium

December 10th 2024

Evolving Treatment Strategies: Managing Advanced Prostate Cancer

Latest Conference Coverage

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

View More Latest Conference CoverageAdvertiseAbout OncLiveEditorial BoardMJH Life Sciences brandsContact UsPrivacyTerms & ConditionsDo Not Sell My InformationContact Info

2 Commerce Drive Cranbury, NJ 08512

609-716-7777

© 2024 MJH Life Sciences All rights reserved.HomeAbout UsNewsContact